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ABSTRACT: Comparing the harmful health effects related to two different tobacco products
by applying common risk assessment methods to each individual compound is problematic.
We developed a method that circumvents some of these problems by focusing on the change
in cumulative exposure (CCE) of the compounds emitted by the two products considered.
The method consists of six steps. The first three steps encompass dose-response analysis of
cancer data, resulting in relative potency factors with confidence intervals. The fourth step
evaluates emission data, resulting in confidence intervals for the expected emission of each
compound. The fifth step calculates the change in CCE, probabilistically, resulting in an un-
certainty range for the CCE. The sixth step estimates the associated health impact by com-
bining the CCE with relevant dose-response information. As an illustrative case study, we
applied the method to eight carcinogens occurring both in the emissions of heated tobacco
products (HTPs), a novel class of tobacco products, and tobacco smoke. The CCE was esti-
mated to be 10- to 25-fold lower when using HTPs instead of cigarettes. Such a change indi-
cates a substantially smaller reduction in expected life span, based on available dose-response
information in smokers. However, this is a preliminary conclusion, as only eight carcinogens
were considered so far. Furthermore, an unfavorable health impact related to HTPs remains
as compared to complete abstinence. Our method results in useful information that may help
policy makers in better understanding the potential health impact of new tobacco and related
products. A similar approach can be used to compare the carcinogenicity of other mixtures.
KEY WORDS: Carcinogenicity; cumulative exposure; heated tobacco; relative potency; tobacco prod-
ucts
1. INTRODUCTION
Many new types of tobacco product have
emerged on the market in recent years, the most
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prominent examples being electronic cigarettes and
heated tobacco products (HTPs) (El-Toukhy et al.,
2018; Elias, Dutra, St. Helen, & Ling, 2018; Hair
et al., 2018; Kim, Yu, Lee, & Paek, 2018; Nyman
et al., 2018; Tabuchi et al., 2018). Many of these new
tobacco and related products (TRPs) claim to be
“harm reduction” or “reduced risk” products (Mar-
tin et al., 2018). Some jurisdictions include provisions
regarding modified risk products in their laws. For in-
stance, the U.S. Family Smoking Prevention and To-
bacco Control Act defines a “Modified risk tobacco
product as a tobacco product sold or distributed to
1 0272-4332/20/0100-0001$22.00/1
C© 2020 The Authors. Risk Analysis published by Wiley Periodicals, Inc. on behalf of Society for Risk Analysis
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
2 Slob et al.
reduce harm or reduce the risk of tobacco-related
disease associated with commercially marketed
tobacco products.” An example of an HTP evaluated
as modified risk product is the IQOS device that is
used to heat tobacco sticks (HEETS) (FDA, 2017).
HEETS, containing reconstituted tobacco and addi-
tives such as nicotine and flavorings, are heated with
an IQOS. The resulting emissions, which are inhaled
by the user, are claimed to contain less harmful
compounds and should therefore be less hazardous
to human health than conventional cigarettes.
According to the World Health Organization
(WHO) (WHO, 2014), regulators need to assess
the validity of implicit or explicit health claims of
new TRPs for the individual user by evaluating
various criteria. One of those is that, compared to a
reference product, the new TRP needs to have lower
emissions or toxicants levels in mainstream smoke,
lower overall toxicant exposure, and fewer detri-
mental effects at the individual level. In addition, the
potential impact on public health at the population
level needs to be estimated by assessing the total
prevalence of all TRP users, dual users of TRPs
and cigarettes, and original TRP users switching to
cigarette smoking (“gateway” effect).
Establishing the health impact of smoking
cigarettes or alternative tobacco products is a
complex issue. Novel tobacco products often show
reduced emissions but it remains unclear how this
translates to reduction of cigarette smoke-induced
health effects. Cigarette smoke is a complex mixture
containing more than 7,000 compounds with varying
toxicological effects, at least 63 of which may cause
cancer (USDHHS, 2014). In addition to different
types of effect, there is also the issue of varying
potency (the dose at which effects start to occur)
and varying severity (e.g., cancer vs. mild lung
lesions). Several methods for hazard and/or risk
prioritization of compounds in cigarette smoke have
been proposed (Burns et al., 2008; Cunningham,
Fiebelkorn, Johnson, & Meredith, 2011; Fowles &
Dybing, 2003; Lachenmeier & Rehm, 2015; Pankow,
Watanabe, Toccalino, Luo, & Austin, 2007; Xie
et al., 2012). Stephens (2017) proposed a method for
comparing the potential risks of alternative products
relative to that of cigarettes by using the inhalation
unit risk, also called cancer potency factor (CPF).
While his general approach of taking the sum of the
potency-adjusted emissions is valid, inhalation unit
risks suffer from various drawbacks as acknowledged
in his paper. For example, they are determined in a
nonstandardized way, and, as a result, they can be
expected to result in an imprecise estimate of the po-
tency of each constituent compound in the product,
and hence of the product as a whole. This is discussed
in more detail below, and illustrated by some results
(Appendix C in Supporting Information). Another
way of estimating relative potencies is by applying
the benchmark dose (BMD) approach, which has
a solid statistical foundation, and relies on the
dose-response data rather than on simply assuming
that the dose response is linear starting from a more
or less coincidental reference point. Furthermore, it
is important to take the quantitative uncertainties in
the underlying data (both on exposure and on dose
response) into account, and explicitly quantify the
ensuing uncertainty of the outcome, without which
unwarranted decisions might be taken by policy
makers.
We have developed a method that uses relative
potency estimates based on dose-response modeling
and evaluates the uncertainties in the underlying
data. The resulting change in cumulative exposure
(CCE) may be used to assess the impact on health
effects in a semiquantitative way. Before providing
a more extensive discussion of the method by an
application to a case study, we will first describe the
rationale of the approach in conceptual terms.
2. CONCEPTUAL SUMMARY OF THE
METHOD
The method we propose relies on the core
method of dose addition, a method frequently ap-
plied to assessing the risk of combined exposures to
multiple compounds (Meek et al., 2011). It assumes
that the dose responses (for the same type of effect)
of the compounds involved are parallel (on log-dose
scale). This assumption appears to be generally valid
(EUROMIX, 2017), and can be evaluated in retro-
spect by examining the results of the dose-response
analysis (see Supplementary Material, SM2). It
might be that some of the compounds in tobacco
smoke deviate from dose addition and are subject
to synergism or antagonism. However, interaction
among chemicals seems to be rare (EUROMIX,
2017), and even if it occurred, the ensuing under- or
overestimating of risks would occur in both products
that are being compared. Since we quantify the ratio
of the cumulative exposures in each product, over-
or underestimations due to interaction would at least
partly cancel out (see expression (1)).
Dose addition involves expressing the dose of
the mixture, consisting of constituent compounds
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Fig. 1. Schematic representation of the concept of dose addition. The multiple doses of the mixtures (left plot; only two compounds shown
here in this three-dimensional figure; in reality, there is a response surface rather than a curve) are translated into an equipotent dose
of one of the constituent compounds, called the reference compound (right plot). Note that the dose-response curve in these plots may
be unknown; nonetheless, we can assume that the response at the mixture dose will be similar to that of the single dose of the reference
compound.
each with its own dose, as an equipotent dose of one
of the constituent compounds (called the reference
compound). For a schematic illustration, see Fig. 1.
Using this method, we can transform the problem of
having a tobacco product with multiple compounds
to a hypothetical product that only contains the
reference compound with a dose (emission) that
would result in the same effect as the mixture in the
real tobacco product. In this way, the difficulty of
trying to find the response to multiple compounds
in the tobacco product is reduced to that of finding
the response of a single dose related to a single com-
pound. The latter single dose is termed cumulative
exposure below.
A second aspect of reducing the problem into
more tractable terms is by considering the ratio of
the cumulative exposure in one product (e.g., HTP)
relative to that of another product (e.g., combustible
cigarette). This ratio expresses the CCE between
both products. As a first advantage, the CCE does
not depend on the choice of the reference compound.
The great advantage of the CCE is that for making
inferences on the approximate health impact of
switching between tobacco products we can make in-
ferences directly based on human dose-response in-
formation related to cigarette smoking, as discussed
below (see Step 6). In this way, the extrapolation
of animal dose response into human dose response,
with its associated uncertainties, can be avoided. The
assumption needed here is that the relative potency
factors (RPFs), estimated from animal data, are a
reasonable approximation of the RPFs in humans. In
risk assessments of mixtures based on dose addition,
this assumption is always implicitly made.
The third aspect of the method is the evaluation
of uncertainties in the underlying data, due to
limitations or other weaknesses in the available data.
These are uncertainties in the estimated emissions
of the constituent compounds (due to limitations
in the measurements), as well as the uncertainties
in the estimated RPFs (due to limitations in the
dose-response data). The uncertainties are trans-
lated in the ensuing uncertainty in the final outcome:
the estimated CCE. To illustrate the importance of
knowing the latter uncertainty, imagine that the CCE
is estimated to be a 20-fold decrease in cumulative
exposure for a given novel tobacco product.
However, when the evaluation of the uncertainty
in the value resulted in a range from 1.3-fold to 120-
fold, there would not be much ground for decision-
making based on the point estimate of 20-fold: a quite
small CCE of 30% cannot be excluded. If, on the
other hand, the uncertainty range was found to be be-
tween 10-fold and 40-fold, then this would constitute
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support that the alternative product does indeed
lead to a (substantial) favorable health impact.
The method is graphically summarized in Fig. 2
in six separate steps.
3. ILLUSTRATIVE CASE STUDY
To illustrate how the method works in a practical
analysis, it was applied to eight carcinogens common
to both HTPs and cigarettes, for which both emission
and cancer dose-response data were available. This
section discusses the six steps involved in the method
in somewhat more detail. More details can be found
in the Supplementary Material.
3.1. Step 1: Carcinogenicity Data and Severity
Categories
Carcinogenicity data were obtained from the
carcinogenic potency database (CPD, 2018) and
from the US National Toxicology Program database
(NTP, 2018). In addition to the eight compounds di-
rectly relevant for the evaluation, the dose-response
analyses in steps 2 and 3 (see below) were performed
using an additional nine compounds with inhalation
carcinogenicity data for an exposure period longer
than 96 weeks. These nine compounds were addi-
tionally included in the BMD analysis to reduce
the uncertainty in the estimated RPFs, due to a
more precise estimate of the steepness parameter
in the dose-response model when more compounds
provide information on that value (as a sort of
read-across; see Slob & Setzer, 2014, p. 288, for an
explanation of this principle). All compounds used
in the dose-response analyses are listed in Table I.
Severity categories were assigned to each mea-
sured endpoint because cancer dose-response data
may relate to distinct endpoints, reflecting different
stages of the carcinogenicity process, related to
varying degrees of severity. Clearly, a dose that
causes a 10% increase in the fraction of animals
with a preneoplastic lesion such as hyperplasia is not
equipotent to a dose that causes a 10% increase in
animals with malignant carcinomas. We assigned one
of the following “lesion categories” to each endpoint
in our database: (1) preneoplastic lesion, (2) benign
tumor(s), (3) malignant tumor(s) in a single organ,
(4) malignant (metastasizing) tumors in different
organs, and (5) tumor bearing animals (Hernandez,
van Benthem, & Slob, 2012). These assignments
were based on a full list of possible endpoints in
cancer studies, compiled by an experienced pathol-
ogist. Steps 2 and 3 below were performed for each
severity categories 2–5 separately.
3.2. Step 2: Selection of Data Sets with the Lowest
BMD for Each Compound
The BMD software PROAST (see www.
proast.nl) version 65.12 was used for dose-response
analysis. In this step, the dose-response analysis
was performed to determine the individual data
set with the lowest BMD estimate for each com-
pound. An individual data set was defined as one
where all associated factors were at the same level
(same compound, tissue, sex, tumor type, exposure
duration, study duration). The results of this first
dose-response analysis are shown in SM2.
3.3. Step 3: Estimation of RPFs
In Step 3, the critical data sets (for each severity
category) were combined for BMD analysis to
estimate the RPF for each compound. The dose-
response curves for the different compounds can be
described by parallel dose-response curves (on log-
dose scale), and the distance between each pair of
these curves is the log of the RPF. The RPF can be es-
timated by the ratio of the BMDs for both chemicals.
Due to the curves being parallel on log-dose scale,
the BMD ratio does not depend on the value of the
BMR (note that a ratio turns into a difference or dis-
tance on log-scale). 1,3-Butadiene (but) was selected
as a reference compound because dose-response data
were available for all severity categories 2–5. The
reason for choosing the same reference compound
for each severity category was that BMDs might sys-
tematically differ among these categories, whereas
estimated RPFs might be less dependent on category.
An exponential model (see SM2) was used for esti-
mating the RPF for each of severity categories 2–5.
This resulted in RPFs for 9, 13, 4, and 13 compounds
related to severity categories 2–5, respectively.
These were translated into a single RPF confidence
interval for each compound (see SM2), resulting in
the confidence intervals shown in Table II.
3.4. Step 4: Evaluation of Emission Data
An inventory was made up of smoke com-
ponents measured in HTPs and in conventional
cigarettes (Auer, Concha-Lozano, Jacot-Sadowski,
Cornuz, & Berthet, 2017; Bekki, Inaba, Uchiyama,
& Kunugita, 2017; Jaccard et al., 2017; Li et al., 2019;
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Fig. 2. Graphical illustration of CCE derivation (CCE = change in cumulative emission; Ecig = cigarette emissions; Ehtp = heated tobacco
product [or alternative tobacco product] emissions; RPF = relative potency factor).
Step 1) Categorization of tumors in severity classes: for each cancer study, observed lesions were categorized into either preneoplastic
lesion, benign tumor(s), malignant tumor(s) in a single organ, malignant tumor(s) metastasizing in different organs, or tumor-bearing
animals as suggested by an experienced pathologist.
Step 2) For each tumor severity category, dose-response analysis was performed for each individual data set (same tissue, sex, tumor type,
exposure duration, and study duration).
Step 3) For each tumor severity category, a critical data set for each compound was selected based on the lowest BMD estimate; BMD
analysis was performed on the combined critical data sets (one per compound), resulting in confidence intervals for the RPF. The results
for the various severity categories were combined, as described in the final part of Supplementary Material SM2.
Step 4) Determination of confidence intervals for mean emissions, based on data from smoking machine studies.
Step 5) The change in cumulative emission (CCE) was derived by taking the uncertainty in the RPF and the emissions between cigarettes
and HTPs into account, resulting in an uncertainty range for the CCE.
Step 6) The value (uncertainty range) of the CCE is translated into an estimate of the health impact, based on available dose-response data
of smokers, and generic knowledge on the steepness of dose responses in general. A CCE of 1 would be associated with no change in health
impact, while a factor of 10 or more may be expected to result in a substantial reduction in harm, when a user switches from cigarettes to
HTP. A CCE (substantially) smaller than 1 would indicate an increase in harm.
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Table I. Inventory of Compounds with Emission, Carcinogenicity, and Inhalation Unit Risk Data
Compound
Abbre-
viation
IARC
category
Emission
data (CS
and HTP)
Carcino-
genicity
data
Inhalation
unit risk
data
Acrylonitrile can 2B   
Acetaldehyde
a
ald 2B   
1,3-Butadiene
a
but 1   
Ethylene oxide eox 1   
Formaldehyde
a
fal 1   
Benzo[a]pyrene
a
bap 1   
Nitrobenzene nbz 2B   
Propylene oxide prp 2B   
Allyl glycidyl ether age NC 
Alpha-methyl styrene ams 2B 
1,2-Dibromo-3-chloropropane dbcp 2B  
1,2-Dibromoethane dbe 2A  
Decalin dcn NC 
Hydrazine hyr 2A  
Isobutyl nitrite isn 2B  
Naphthalene nap 2B  
Propylene glycol mono-t-butyl ether pge 2B 
aWHO TobReg list of smoke components for mandated lowering (Burns et al., 2008). CS = cigarette smoke; HTP = heated tobacco product;
NC = not classified by IARC.
Mallock et al., 2018; Schaller, Pijnenburg, Ajithku-
mar, & Tricker, 2016; Uchiyama et al., 2018). As
we are interested in the relative change in emissions
between HTP and cigarette, we selected the study by
Schaller, Pijnenburg, et al. (2016), as they measured
the emissions under similar circumstances in both
products, using similar assumptions on smoking
behavior. When there is knowledge about different
smoking behaviors in both products (e.g., # puffs
per minute is larger in one product), this can be
taken into account in our method, as illustrated in
Appendix A of Supporting Information.
The concentrations in Schaller, Keller, et al.
(2016) were compared to various other publications
reporting HTP emission data (Jaccard et al., 2017;
Li et al., 2019; Mallock et al., 2018; Uchiyama et al.,
2018), to make sure that the concentrations men-
tioned in this publication were in the same range.
Some differences were found, which might be ex-
plained by the different smoking regimes used; how-
ever, it is not the emissions themselves but the ratio
between emissions that affects the estimated value
of CCE. As long as both products were measured in
the same and relevant way, the ratio of the measure-
ments should provide the appropriate information.
Table III shows the uncertainty in the mean
emissions for any of the two products expressed
as (two-sided) 90% confidence intervals based on
replicate measurements (see SM2).
3.5. Step 5: Derivation of Change in Cumulative
Emission
The cumulative emission of the eight compounds
for both cigarette and HTP was derived taking into
account the RPF (relative to 1,3-butadiene) for
each compound. This resulted in an estimate of
the cumulative emission, expressed in amounts of
1,3-butadiene. The ratio of the two estimates reflects
the change in cumulative emission of the alternative
product (e.g., HTP) as compared to the cigarette:
CCE = change in cumulated emission =
∑
i Ecigi . RPFi∑
i Eht pi . RPFi
(1)
where the subscript i denotes a particular compound,
and Ecig and Ehtp the emission in µg/cigarette and in
µg/HTP stick, respectively. A value of CCE larger
than 1 indicates a decrease in cumulative emission
relative to cigarette smoke, and vice versa. It should
be noted that selecting another reference compound
would result in the same estimate of the CCE.
We combined the confidence intervals for the
emissions of the eight compounds (in cigarette and
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Table II. Confidence Intervals of the RPFs of Each Compound
Relative to 1,3-Butadiene, Estimated from BMD Analysis of the
Dose-Response Data Available for Inhalation Carcinogenicity
Studies. See SM2 for More Detailed Data Per Severity Category,
and How They Were Integrated into One Single Confidence
Interval for Each Compound
Substance LB UB
1,3-Butadiene *
a
(BMD) 30.3 56
Acrylonitrile
a
5.76 192
Allyl glycidyl ether 0.089 2.69
Acetaldehyde
a
0.469 0.931
Alpha-methyl styrene 0.583 5.39
Benzo[a]pyrene
a
29.3 187
1,2-Dibromo-3-chloropropane 8.95 26.6
1,2-Dibromoethane 0.575 1.67
Decalin 0.0175 0.11
Ethylene oxide
a
21.7 71.5
Formaldehyde $ 68.2 129
Hydrazine 5.65 560
Isobutyl nitrite 0.176 3.7
Naphthalene 0.339 0.726
Nitrobenzene
a
0.115 11.3
Propylene glycol mono-t-butyl ether 0.61 5.9
Propylene oxide
a
1.85 22.8
aEmission data also available; LB = 5% lower uncertainty bound;
UB = 95% upper uncertainty bound.
Table III. Uncertainty Bounds for the (Geometric) Mean
Emissions Per Stick (HTP) or Per Cigarette Based on Data from
Schaller, Keller, et al. (2016)
HTP Emission
(µg/stick)
Cigarette Emission
(µg/cigarette)
Compound LB UB LB UB
Acrylonitrile 0.142 0.320 30.82 32.71
Acetaldehyde 143 321 1,048 2,358
Benzo[a]pyrene 0.00092 0.00207 0.0093 0.0209
1,3-Butadiene 0.212 0.477 51.02 114.79
Ethylene oxide 0.162 0.364 21.14 47.56
Formaldehyde 3.560 8.010 41.53 93.45
Nitrobenzene 0.00006 0.00051 0.00015 0.0327
Propylene oxide 0.102 0.229 1.005 2.260
HTP = heated tobacco product; LB = 5% lower uncertainty
bound; UB = 95% upper uncertainty bound.
in HTPs) with the confidence intervals of the RPFs,
and used that in a probabilistic approach to calculate
the overall uncertainty in the estimated CCE. The
probabilistic evaluation is done by defining a (log-
normal) distribution for Ecig, Erpf, and RPF, based on
their lower and upper (two-sided) 90% confidence
bounds, reported in Tables II and III. Then, for each
of these three distributions, a large number (n) of
values is sampled and for each combination of the
three randomly sampled values, the expression is
evaluated, resulting in n values for CCE. Together,
these values constitute the uncertainty distribution
for CCE, the 5th and 95th percentiles of which define
a two-sided 90% confidence interval for the CCE.
As shown in Table I, there were eight com-
pounds for which both emission data and RPF
estimates were available. Based on these eight
compounds, the probabilistic evaluation of the CCE
(see expression (1)) resulted in an uncertainty range
of 9.6–26. In other words, the cumulative emission
for this eight-compound mixture is estimated to be
somewhere between 10- and 25-fold lower (after
rounding off), when a given individual consumes the
same number of HTPs instead of cigarettes (with
similar smoking behavior for both products).
3.6. Step 6: Translating CCE Into Health
The final question to be answered is what
(individual) health impact may be associated with a
decrease in (cumulative) exposure by a factor some-
where between 10 and 25. As one of the advantages
of the proposed method, this 10- to 25-fold CCE
relates to the whole mixture (considered), or, equiv-
alently, to any single compound used as a reference
(see Fig. 1). Therefore, we can use our generic knowl-
edge about the typical steepness of a toxicological
dose-response relationship for a single compound
to make inferences on the associated health impact.
Based on the steepness of a dose response, it can be
inferred whether a decrease in dose by 10- or 25-fold
will lead to a minor or a substantial reduction of the
effect. However, quantal dose-response relationships
(describing incidence as a function of dose) are not
suitable for that purpose, as they will be steeper in
animals than in humans, because animals in toxicity
studies are much more homogeneous than humans.
Continuous dose-response relationships are not
sensitive to interindividual variation and there is
no reason that they would differ in shape among
animals, including humans. This is supported by a
reanalysis of a large number or dose-response data
sets from rats and mice (Bokkers & Slob, 2007).
From general experience and systematic reviews
(Slob & Setzer, 2014), it is known that dose responses
related to continuous endpoints are in general quite
homogenous regarding their steepness: the ratio
between BMD10 and BMD05 (doses associated with
a 10% and a 5% effect size) is usually close to, or
less than 2. For the time-to-tumor dose response
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reported in a mega-rat study (Peto, Gray, Brantom,
& Grasso, 1991), the BMD10/BMD05 ratio was
found to have a confidence interval of 2 up to 2.6
(Slob & Setzer, 2014). So, in the rat, a CCE of 2 to
2.6 would reduce a 10% reduction in life span to a
5% reduction. This implies that a CCE between 10
and 25 should be associated with an even greater
(favorable) impact on life span.
Another approach for relating a CCE with
health impact is to use dose-response information on
smokers. For example, a recent study (Inoue-Choi
et al., 2018) compared nondaily to daily smokers
(50 vs. 600 cigarettes per month) and found that life
expectancy for both groups was reduced by 5 and
10 years, respectively. The difference in exposure
to cigarette smoke (i.e., just over 10 fold) was ap-
parently associated with a five-year longer expected
life span. As this difference in exposure between
the nondaily and daily smokers is comparable to the
(lower bound) CCE value of 10-fold between HTP
and cigarette, it may be inferred that the associated
health impact of that CCE is substantial. At the same
time, nondaily smokers were reported to have a
five-year shorter life span compared to nonsmokers,
and this indicates that HTP would still be associated
with a substantial (five years) decrease in life span.
While the study in rats indicated that a reduction
in healthy life span from 10% to 5% would be
associated with a decrease in dose by 2- to 2.6-fold,
the study on smokers related a roughly similar
change in life span to a decrease in exposure by a
factor of around 10. This seems to contradict the
assumption just made that (continuous) dose re-
sponses are equally steep among species. However,
this might be explained by the fact that the observed
dose response on life expectancy in the (non)daily
smokers integrates various types of effect, including
cancer and cardiovascular effects, which may lead to
less steep dose response for overall life expectancy.
Overall, the conclusion seems to be warranted
that consuming HTPs instead of cigarettes will
be associated with a substantial increase in life
expectancy, for the subgroup of smokers who would
die from cancer. However, a substantial negative
health impact is expected to remain from consuming
HTPs as compared to total abstinence from tobacco
products.
4. DISCUSSION
We have developed a methodology for evalu-
ating the potential magnitude of the health impact
when comparing a cigarette smoker with a consumer
of an alternative tobacco product (with similar
consumption pattern; see Appendix A of Supporting
Information if consumption pattern is known to
be different). The method we propose here was
applied to cancer, but we intend to examine whether
it can be adapted for other types of effect (e.g.,
cardiovascular) that may be caused by the use of
tobacco products. In addition, the method can also
be applied to evaluate the carcinogenicity of other
complex mixtures. Our method does not consider
the potential impact of the alternative product on
public health at the population level. The required
information (e.g., total prevalence of all TRP users,
dual users of TRPs and cigarettes, and original TRP
users switching to cigarette smoking) is not available
when a new TRP is launched on the market, and can
only be roughly estimated by information from other
markets, similar products, or estimated product
appeal for several relevant user groups.
Estimating cancer risk (as one potential type
of effect that may be caused by tobacco use) by
applying current risk assessment methods to each
single component of the mixture is an almost im-
possible undertaking because of the large number of
compounds present in cigarette smoke, and because
current methods aim at safety assessment rather
than estimating health effects. Furthermore, we
found that inhalation unit risk values (one of the
current methods of cancer risk assessment) are
not (or barely) informative regarding the (relative)
potencies of the compounds (see Appendix C of
Supporting Information). Instead, we estimated the
relative potencies of the compounds based on dose-
response modeling, which is the (statistically) appro-
priate method for that purpose. By focusing on the
estimation of the CCE, we circumvent various diffi-
culties that would occur when applying current risk
assessment methods to each individual compound. It
is much easier to draw conclusions on health impact
based on the CCE relative to the cigarette, as shown
in the discussion of Step 6 of the case study. The main
assumption in our calculation of the CCE is that the
relative potencies among compounds estimated from
animal data approximately hold for humans. Based
on the CCE, the health impact can be inferred from
general dose-response information on the steepness
of dose-response curves in general, or from available
dose-response information in smokers with various
use intensities. Thus, we found that the CCE most
likely amounts to a factor between 10 and 25 when
comparing a leading variant of HTPs with cigarettes,
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and that even the lower bound of this uncertainty
range would be associated with a substantial health
impact in favor of HTP. Obviously, the health
impact will be greatest for habitual smokers when
they switch to HTP at a young age.
4.1. Some Advantages of the Method
A major advantage of our approach is that it
makes the uncertainty in the final estimate of the
CCE visible, which is not possible in approaches
based on inhalation unit risk. As the probabilistic
calculation of the CCE showed, the uncertainty in
that value (range of 10- to 25-fold) in this particular
case study is relatively small, and allows for the
conclusion that the reduction in cumulative emission
is substantial, even for the lower bound of the CCE
estimate. However, in other cases, e.g., when data
are more limited for some of the compounds, the es-
timated CCE may be much more uncertain. In those
cases, a single point value, without the uncertainty
bounds, may indeed be misleading, and inaccurate
conclusions can be easily drawn.
A specific point in Steps 2 and 3 is that we applied
dose-response analysis to the combined data sets
available in a single model fit. This method allows for
an estimate of the RPF for data-poor carcinogens, or
carcinogens with no significant increase in incidence
with dose; this is possible by applying the covariate
approach in the dose-response analysis (Soeteman-
Hernandez, Johnson, & Slob, 2016). Such poor or
weak data sets may have resulted in RPF confidence
intervals with lower bound = 0 and upper bound =
infinite, i.e., totally noninformative. In the covariate
approach, even data sets with a nonsignificant trend
will result in a useful RPF confidence interval (with
0 lower bound but with finite upper bound), and that
uncertainty can be evaluated in the probabilistic eval-
uation of the CCE. In this way, the uncertainty of
such poor data sets is propagated into the uncertainty
of the final CCE. Note that very small values of the
RPF will hardly change the value of the CCE.
4.2. Number of Compounds Considered
Our analysis is based on only eight carcinogenic
smoke components, while many more carcinogens
are present in smoke. However, if it were assumed
that these eight compounds are a representative
sample of all carcinogens occurring in smoke, then
increasing the number of compounds in the analysis
will make the estimate of the CCE more reliable, but
most likely not dramatically different. Nonetheless,
it would be better to include more carcinogens in the
analysis when the data are available. For instance,
some compounds might show higher rather than
lower emissions in HTP, which could reduce the
value of CCE. That such is possible was shown by St.
Helen, Jacob Iii, Nardone, and Benowitz (2018) who
claimed that 22 substances were threefold higher and
seven were >10-fold higher in the HTP (IQOS) than
in 3R4F reference cigarette smoke. As long as that
information is not incorporated in an analysis that es-
timates the CCE, it remains unclear how those com-
pounds may influence the CCE and the associated
health impact. When they happen to have a relative
high RPF, they may reduce the value of the CCE,
but if their RPFs are relatively small, they will not.
4.3. Carcinogenicity Dose-Response Limitations
While we have tried to obtain the best possible
estimates of relative potency among compounds,
by using the most recent BMD methodology, and
by taking biological factors into account to our
best ability, there are some remaining issues in the
dose-response analysis that need to be mentioned.
First, all study durations longer than 96 weeks were
considered similar, while it is known that study
duration may have a considerable impact on the
dose response for cancer endpoints (see, e.g., the
mega-mouse study with 2-acetylaminofluorine [It-
trich et al., 2003]). To further improve the estimation
of RPFs, dose-response models should be developed
that can take study duration into account in an effi-
cient manner. Given the current state of the science,
our approach was to assume no differences in study
duration. Fortunately, the majority of the data sets
were related to study durations around 100 weeks
with only a few in the range of 120 or 150 weeks.
Therefore, the bias in the RPF estimates may be lim-
ited. Another issue is that the RPFs were based on
data sets with largely different background response.
We used extra risk as a way to correct for background
response, as this is the default way of expressing the
BMR in most international organizations (e.g., EPA
[USEPA, 2012], EFSA [EFSA, 2017], WHO [1994],
[WHO-IPCS, 2014]). However, the problem is that it
is not entirely clear how to properly adjust for back-
ground response (WHO-IPCS, 2014). This problem
may also lead to bias in some of the RPF estimates.
Yet, it seems unlikely that it will have a substantial
impact on the overall estimate of the CCE.
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4.4. Using Alternative Data
As carcinogenicity studies are currently only
performed when considered indispensable, alterna-
tive approaches of estimating RPFs for carcinogenic
compounds need to be explored. One promising
avenue is the correlation found between the BMDs
derived from in vivo micronucleus tests (i.e., a
short-term genotoxicity test that measures chromo-
somal aberrations) and BMDs from carcinogenicity
studies (Bemis et al., 2016; Johnson et al., 2014, 2014;
Soeteman-Hernandez, Fellows, Slob, & Johnson,
2015; Soeteman-Hernandez et al., 2016; Wills, John-
son, Battaion, Slob, & White, 2017; Wills, Johnson,
et al., 2016; Wills, Long, et al., 2016). Given this
correlation, it directly follows that data from the in
vivo micronucleus test might be a suitable surrogate
for estimating RPFs of carcinogens. Regarding
nongenotoxic carcinogens, a possible option is to
use subchronic No-Observed Adverse Effect Level
(NOAELs) (or preferably, BMDLs) because they
have been shown to correlate well with the BMDs
from carcinogenicity studies (Braakhuis et al., 2018).
4.5. Implications for Policy and Practice
Our method may have significant implications
for policy and practice, as it provides a tool to
evaluate the health impact of an individual who
switches from smoking cigarettes to new TRPs.
An outcome of the method is an uncertainty
range for the CCE, which is informative by itself
at least for comparison among various new TRPs.
By making the uncertainty in the CCE visible for
any specific case, policy makers know if available
scientific information is weak or sufficiently strong
to provide a basis for their decisions. Furthermore,
the potential health impact associated with specific
values of the CCE can be estimated based on gen-
eral information on the steepness of toxicological
dose-response relationships in general, or on more
specific dose-response information on smokers.
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Figure B1. Uncertainty ranges of the RPF-adjusted
emissions (expressed as butadiene equivalents) of
eight carcinogenic compounds in cigarette (dashed
lines) and in HTP emissions (solid lines).
Figure C1 Inhalation unit risks (also called cancer po-
tency factors [CPFs]) plotted against RPFs both on a
log scale.
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